Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First RemissionAlexandre Bazinet, Tapan M. Kadia, Jo Ishizawa et al.|Blood|2024Cited by 4
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemiaNitin Jain, William G. Wierda, Alessandra Ferrajoli et al.|Blood|2025Cited by 3
Supplemental Information from Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Michael Andreeff|Unknown|2023Cited by 0